Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system
Unexpected AEs of celecoxib in neurological diseases and cancer have been identified, offering valuable insights for monitoring and risk assessment in future clinical applications.
Authors
- Yi Du (ORCID: https://orcid.org/0000-0001-9568-0907)
- Chun Yang (ORCID: https://orcid.org/0000-0001-5813-0914)
- Xiaolin Cai (ORCID: https://orcid.org/0000-0001-6852-0908)
- Mingjun Zhong (ORCID: https://orcid.org/0000-0002-1525-1270)
- Mianhai Chen (ORCID: https://orcid.org/0009-0004-9521-6812)
- Mengyi Hu (ORCID: https://orcid.org/0009-0003-6498-2883)
- Weichui Zhang (ORCID: https://orcid.org/0000-0001-8501-3588)
- Jinfeng Zhu (ORCID: https://orcid.org/0000-0002-1737-0185)
- Mengting Zhang
- Wenqi Zeng
- Yi Liu (ORCID: https://orcid.org/0009-0003-6743-6415)
Institutions
- Guangdong Medical College (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- Dongguan People’s Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1080/14740338.2025.2487140
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Southern Medical University
- Research and Development